A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of Her2-Overexpressing Esophageal Adenocarcinoma
Principal Investigator
Howard Safran, MD
Status
Terminated
Date Opened To Accrual
December 13 2010
Date Closed to Accrual
November 09 2015
Date of Study Termination
August 15 2023
Disease Site
Gastrointestinal [GI]
Esophageal
Phase
III
Developmental Therapeutics
No
Primary Objective
To determine if trastuzumab increases disease-free survival when combined with trimodality treatment (radiation plus chemotherapy followed by surgery) for patients with HER2-overexpressing esophageal adenocarcinoma
Patient Population
Pathologically confirmed HER2 expressing adenocarcinoma of the esophagus centrally assessed within 56 days prior to Step 2 registration; primary adenocarcinoma of the esophagus involving the mid (up to 25 cm), distal and/or esophagogastric junction.
Target Accrual
197
Patient Study Webpage
There is no available patient study webpage available for this trial at this time.